Revisiting the role of pregnancy zone protein (PZP) as a cancer biomarker in the immunotherapy era
Jie Huang(Menlo School), Shenglin Ma(Hangzhou Medical College), Xueqin Chen(Institute of Electronics), Ying Xu(Chengdu Medical College), Juan Shen(BGI Group (China)), Yao Qiu(Hangzhou Cancer Hospital), Yidan Chen(Hangzhou Cancer Hospital), Xin Li(Heilongjiang Bayi Agricultural University)
Cited by 7
Related Papers
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590
The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis
|Proceedings of the National Academy of Sciences|2005|427
Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion
|Nature Communications|2022|243
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial
|The Lancet Oncology|2012|228
Obacunone alleviates ferroptosis during lipopolysaccharide-induced acute lung injury by upregulating Nrf2-dependent antioxidant responses
|Cellular & Molecular Biology Letters|2022|170